OakChart

Arvinas Inc

ARVNHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

6.91-0.01 (-0.14%)
2026-11-12 05:15 CET
Market cap
452.50 USD m
Revenue, TTM
275.30 USD m
Net income, TTM
-9.50 USD m
Free cash flow, TTM
-159.80 USD m
EPS diluted, TTM
-0.18
P/E
-
Compare

Price

ARVN against its 20, 50 and 200-day averages
2050200beat
8.0010.001.5M3.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ARVNclose 6.9120-day 7.2750-day 7.72200-day 9.466.9152w low

52.4% under the 52-week high of 14.51 on 10 Mar 2026. 52-week low 6.33 on 9 Nov 2026. Last 15 sessions, 26.9% high to low

Volume 0.91× normal · the line is the 50-bar volume average

Profile

ARVN
52-week range, 7% of the way up
6.3314.51

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

IndexRUT
Employees246
IPOSep 27, 2018
Beta1.81
ATR, 14d0.44
Rel volume0.91
Short float9.80%
Insider own10.38%
Inst own81.31%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap452.51M
Enterprise Value-98.29M
Income-9.50M
Sales275.30M
Book/sh7.84
Cash/sh8.53
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees246
IPOSep 27, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S1.64
P/B0.88
P/C0.81
P/FCF-
EV/EBITDA-
EV/Sales-0.36
Quick Ratio8.39
Current Ratio8.39
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.18
EPS next Y-3.09
EPS next Q-0.71
EPS this Y114.20%
EPS next Y-2008.95%
EPS next 5Y-
EPS past 3/5Y40.13% 17.70%
Sales past 3/5Y25.96% 64.50%
EPS Y/Y TTM81.44%
Sales Y/Y TTM-11.85%
EPS Q/Q-71.89%
Sales Q/Q-98.81%
EarningsNov 03 BMO
EPS/Sales Surpr.10.65% -95.96%

Ownership

Insider Own10.38%
Insider Trans-0.79%
Inst Own81.31%
Inst Trans3.23%
ROA-1.31%
ROE-1.76%
ROIC-1.83%
Gross Margin95.02%
Oper. Margin-10.10%
Profit Margin-3.45%
SMA20-4.90%
SMA50-10.52%
SMA200-26.93%
Trades-

Technical

Shs Outstand65.50M
Shs Float58.68M
Short Float9.80%
Short Ratio7.25
Short Interest5.75M
52W High14.51 -52.38%
52W Low6.33 9.16%
Volatility7.84% 6.17%
ATR (14)0.44
RSI (14)43.56
Beta1.81
Rel Volume0.91
Avg Volume793.34K
Volume725,762

Performance

Perf Week-6.87%
Perf Month1.02%
Perf Quarter-23.31%
Perf Half Y-29.99%
Perf YTD-41.74%
Perf Year-38.36%
Perf 3Y-53.90%
Perf 5Y-91.93%
Perf 10Y-
Recom2.13
Target Price14.00
Prev Close6.92
Price6.91
Change %-0.14%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Aug 04, 2026DowngradeWWells FargoOverweight → Equal Weight
Jan 06, 2026UpgradeCCitigroupNeutral → Buy$15+117.1%
Oct 15, 2025DowngradeGGoldmanNeutral → Sell$6-13.2%
Sep 24, 2025DowngradeBBofA SecuritiesBuy → Neutral$10+44.7%
Sep 17, 2025ResumedBBarclaysOverweight$16+131.5%
Jun 02, 2025DowngradeLLeerink PartnersOutperform → Market Perform$9+30.2%
May 05, 2025DowngradeTTruistBuy → Hold$11+59.2%
May 02, 2025DowngradeTTD CowenBuy → Hold
May 02, 2025DowngradeJJefferiesBuy → Hold$10+44.7%
Mar 13, 2025DowngradeGGoldmanBuy → Neutral$70 → $15+117.1%

Peers

Mkt cap
TickerCompanyMkt cap
CCCCC4 Therapeutics Inc379.51M
GLUEMonte Rosa Therapeutics Inc880.99M
KYMRKymera Therapeutics Inc11.51B
NRIXNurix Therapeutics Inc1.78B
OLMAOlema Pharmaceuticals Inc703.48M
CELCCelcuity Inc3.16B
RLAYRelay Therapeutics Inc4.36B
IDYAIdeaya Biosciences Inc3.16B
ZNTLZentalis Pharmaceuticals Inc185.72M
PFEPfizer Inc167.86B

Insider trading

latest 14 of 40
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Loomis David KVP, Chief Accounting OfficerNov 09 '26Sale6.362321,47539,961Nov 09 06:04 PM
SUNIL AGARWALDirectorSep 22 '26Proposed Sale8.4923,105196,242Sep 22 04:36 PM
NOAH C BERKOWITZFormer OfficerSep 09 '26Proposed Sale8.8437,200328,915Sep 09 04:16 PM
NOAH C BERKOWITZFormer OfficerSep 04 '26Proposed Sale9.458,30078,438Sep 04 04:23 PM
NOAH C BERKOWITZOfficerAug 04 '26Proposed Sale8.8030,000264,000Aug 04 04:13 PM
NOAH C BERKOWITZFormer AffiliateJul 09 '26Proposed Sale8.4024,000201,528Jul 09 04:12 PM
Saik AndrewChief Financial OfficerJun 24 '26Sale8.165,69646,474187,432Jun 24 05:20 PM
Andrew SaikOfficerJun 24 '26Proposed Sale8.145,84647,586Jun 23 06:09 PM
Cacace Angela MChief Scientific OfficerJun 17 '26Sale7.592,57619,565180,390Jun 18 04:06 PM
Angela CacaceOfficerJun 17 '26Proposed Sale7.422,64219,604Jun 17 08:59 AM
Teel RandyPresident and CEOMay 21 '26Sale9.042,20919,962285,009May 22 04:15 PM
Randy TeelOfficerMay 21 '26Proposed Sale9.102,19719,993May 20 05:34 PM
Saik AndrewChief Financial OfficerMay 11 '26Sale9.9411,139110,693193,128May 13 04:18 PM
Loomis David KVP, Chief Accounting OfficerMay 11 '26Sale9.941,91919,07040,193May 13 04:17 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
IWNiShares Russell 2000 Value ETFAUM: 14.10B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B

News

latest 14 of 100
  • Arvinas to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
  • Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -11.73%
  • Arvinas Misses As Revenue Resets To Royalties; Cost Cuts And A December BCL6 Readout Matter More Than ARV-102's Latest Delay (Earnings Whispers) -5.72%
  • Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation (GlobeNewswire)
  • After Its Vepinu Windfall, Arvinas Must Show A Thinner Pipeline Can Still Deliver (Earnings Whispers)
  • Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026 (GlobeNewswire)
  • Big Pharma Is Pouring Billions Into a New Class of 'Protein Degrader' Drugs (The Wall Street Journal)
  • Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease (GlobeNewswire)
  • Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire)
  • Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate (GlobeNewswire)
  • Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-03-0.820-0.918-0.8200.5012.3913
2026Q22026-08-042.580-0.3742.578249.760.7113
2026Q12026-05-12-0.900-0.924-0.90015.6016.6116
2025Q42026-02-24-1.100-0.514-1.0399.5037.2516
2025Q32025-11-05-0.480-0.697-0.48041.9027.8817
2025Q22025-08-06-0.840-0.931-0.83822.4033.5619
2025Q12025-05-011.140-0.9651.140188.841.8517
2024Q42025-02-11-0.630-0.956-0.62659.2062.0020
2024Q32024-10-30-0.680-0.843-0.682102.460.5617
2024Q22024-07-30-0.490-1.084-0.49076.5033.2713
2024Q12024-05-07-0.970-1.420-0.96825.3032.9418
2023Q42024-02-27-2.530-1.189-2.534-43.1048.3318
2023Q32023-11-07-1.180-1.583-1.18334.6039.4517
2023Q22023-08-08-1.250-1.650-1.24754.5030.9417
2023Q12023-05-05-1.540-1.540-1.53732.5027.9116
2022Q42023-02-23-1.560-1.174-1.55838.0035.7219

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.130-1.945-2.13542.9843.39
2020FY-3.020-2.763-3.01821.8026.24
2021FY-3.820-3.563-3.82046.7074.13
2022FY-5.310-4.940-5.310131.4120.8
2023FY-6.620-5.110-6.61878.50168.51
2024FY-2.770-3.147-2.766263.4264.73
2025FY-1.140-0.712-1.140262.6289.43
2026FY-0.162--277.49
2027FY--3.090--47.79
2028FY--2.740--61.67
2029FY--1.888--94.67
2030FY--1.073--144.3

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-10124411.850.0069.68
2026Q4S2026-11-06124511.850.0069.68
2026Q4S2026-11-05124411.900.0069.68
2026Q4S2026-11-03123411.860.0069.68
2026Q4S2026-11-02120211.550.0069.68
2026Q4S2026-10-30120311.550.0069.68
2026Q4S2026-10-29120216.090.0069.68
2026Q4S2026-10-21130215.510.0069.68
2026Q4S2026-10-18130415.510.0069.68
2026Q4S2026-10-06130815.510.0069.68
2026Q4S2026-08-27130815.510.0069.68
2026Q4S2026-08-20120715.970.0069.68
2026Q4S2026-08-19130717.240.0069.68
2026Q4S2026-08-07130619.500.0069.68

Estimate history

EPS, annual-0.89-25.454-2.135-3.018-3.82-5.31-6.618-2.766-1.14-0.1843
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.682-0.6261.14-0.838-0.48-1.039-0.92.578-0.824
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual7.57914.32442.97621.80253.6131.478.5263.4262.6275.3
Period201720182019202020212022202320242025TTM
Sales, quarterly102.459.2188.822.441.99.515.6249.70.5
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual32.15931.23538.46148.4565353.26868.863.565.5
Period201720182019202020212022202320242025MRQ
Shares, quarterly68.768.87373.270.863.564.565.365.5
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue275.30262.60263.4078.50131.4053.6021.8042.9814.32
Cost of Goods Sold Incl. D&A13.705.206.606.708.206.00---
Gross Profit261.60257.40256.8071.80123.2047.60---
Selling, General and Administrative Excl. Other289.40372.30463.60473.30386.40237.60142.6392.2557.42
Research and Development219.00282.90348.20379.70315.00182.00108.3667.1945.19
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-27.80-114.90-206.80-401.50-263.20-190.00-124.86-51.52-43.80
Interest Expense-----0.100.070.090.06
Unusual Expense5.603.6043.400.000.00-1.000.000.000.19
Net Income Before Taxes-8.80-80.50-198.30-363.90-251.00-185.70-119.33-70.29-41.48
Income Taxes0.700.300.600.9020.90-1.600.000.000.00
Consolidated Net Income-9.50-80.80-198.90-367.30-282.50-191.00-119.33-70.29-41.48
Net Income From Continuing Operations-9.50-80.80-198.90-367.30-282.50-191.00-119.33-70.29-41.48
Net Income-9.50-80.80-198.90-367.30-282.50-191.00-119.33-70.29-239.85
EPS (Recurring)-0.09-1.10-2.34-6.62-5.31-3.83-3.02-2.13-25.44
EPS (Basic, Before Extraordinaries)-0.15-1.14-2.77-6.62-5.31-3.82-3.02-2.13-25.45
EPS (Diluted)-0.18-1.14-2.77-6.62-5.31-3.82-3.02-2.13-25.45
EBITDA-23.20-109.70-200.20-394.80-255.00-184.00-120.83-49.27-43.10
Non-Operating Income (Expense)24.6038.0051.9037.6012.203.305.59-18.682.57
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense25.8334.7669.6856.5659.6541.6830.2320.07-
Price To Sales Ratio1.843.205.2329.1013.8576.62154.0131.488.45
Gross Margin95.0298.0297.4991.4693.7688.81---
Operating Margin-10.10-43.75-78.51-511.46-200.30-354.48-572.69-119.89-305.80
Net Margin-3.45-30.77-75.51-467.90-214.99-356.34-547.35-163.56-1,674.45
Shares Outstanding65.5063.5068.8068.0053.2053.0048.4638.4631.24
Market Capitalization452.50452.501,317.232,264.851,820.914,342.874,039.161,601.54415.71

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.50249.7015.609.5041.9022.40188.8059.20
Cost of Goods Sold Incl. D&A1.2010.201.101.201.301.401.301.60
Gross Profit-0.70239.5014.508.3040.6021.00187.5057.60
Selling, General and Administrative Excl. Other58.4073.8077.2080.0084.6091.50116.10115.80
Research and Development46.9052.3060.0059.8064.3068.0090.8083.30
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-59.10165.70-62.70-71.70-44.00-70.5071.40-58.20
Unusual Expense0.001.601.102.90-0.201.000.000.00
Net Income Before Taxes-53.70169.60-57.50-67.20-34.80-61.5083.10-45.50
Income Taxes0.200.200.100.200.30-0.300.20-0.40
Consolidated Net Income-53.90169.40-57.60-67.40-35.10-61.2082.90-45.10
Net Income From Continuing Operations-53.90169.40-57.60-67.40-35.10-61.2082.90-45.10
Net Income-53.90169.40-57.60-67.40-35.10-61.2082.90-45.10
EPS (Recurring)-0.822.60-0.89-1.01-0.48-0.831.14-0.63
EPS (Basic, Before Extraordinaries)-0.822.61-0.90-1.04-0.48-0.841.14-0.63
EPS (Diluted)-0.822.58-0.90-1.04-0.48-0.841.14-0.63
EBITDA-58.00166.90-61.60-70.50-42.70-69.1072.70-56.60
Non-Operating Income (Expense)5.405.506.307.409.0010.0011.7012.70
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.744.119.567.437.9812.0911.8518.41
Price To Sales Ratio1.841.727.592.932.001.441.205.25
Gross Margin-140.0095.9292.9587.3796.9093.7599.3197.30
Operating Margin-11,820.0066.36-401.92-754.74-105.01-314.7337.82-98.31
Net Margin-10,780.0067.84-369.23-709.47-83.77-273.2143.91-76.18
Shares Outstanding65.5065.3064.5063.5070.8073.2073.0068.80
Market Capitalization452.50536.17677.99761.70625.52537.22482.781,317.23

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments685.401,039.401,266.501,210.801,507.10688.53280.87187.8339.17
Short Term Receivables6.4013.707.208.0025.708.446.285.0326.04
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets8.9014.206.5021.4019.706.113.732.820.32
Total Current Assets700.701,067.301,280.201,240.201,552.50703.09290.88195.6865.53
Net Property, Plant & Equipment13.4016.0014.0017.8016.6014.2510.733.581.30
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets-----0.000.000.000.00
Deferred Tax Assets----5.002.421.33--
Other Assets3.808.1010.4010.8012.500.030.030.020.02
Total Assets717.901,091.401,304.601,268.801,581.60719.79302.97199.2866.85
Short Term Debt Incl. Current Port. of LT Debt1.902.002.101.801.100.950.670.150.16
Accounts Payable24.2013.2017.605.7031.307.124.562.760.60
Income Tax Payable4.803.200.7010.300.00----
Other Current Liabilities111.60211.40236.70277.30229.3041.0127.5820.0717.10
Total Current Liabilities142.50229.80257.10295.10261.7049.0932.8122.9817.85
Long Term Debt7.207.901.303.703.903.093.712.000.15
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities----5.002.421.33--
Other Liabilities134.30292.00386.20405.10534.3022.9438.4337.6348.60
Total Liabilities284.00529.70644.60703.90799.9077.5376.2862.6166.60
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.0061.48
Common Equity433.90561.70660.00564.90781.70642.26226.69136.67-61.23
Total Shareholders Equity433.90561.70660.00564.90781.70642.26226.69136.670.25
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity433.90561.70660.00564.90781.70642.26226.69136.670.25
Total Liabilities & Stockholders Equity717.901,091.401,304.601,268.801,581.60719.79302.97199.2866.85
Book Value Per Share6.838.169.7110.6214.7513.255.894.38-1.90
Tangible Book Value Per Share6.838.169.7110.6214.7513.255.894.38-1.90
Full-Time Employees2464304454152801791338367
Price to Book Ratio0.882.254.952.935.576.416.972.94-1.53
Return on Assets-8.93-16.60-28.55-19.79-16.60-23.34-27.99-31.17-45.90
Return on Equity-16.23-32.56-59.97-41.96-26.83-27.47-38.69-60.59-198.12
Return on Invested Capital-18.32-34.92-55.54-49.68-24.31-18.49-30.51-29.91-6,057.86
Quick Ratio4.924.644.984.205.9314.328.868.523.67
Current Ratio4.924.644.984.205.9314.328.868.523.67

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-9.50-80.80-198.90-367.30-282.50-191.00-119.33-70.29-41.48
Depreciation4.605.206.606.708.206.004.022.250.71
Other Funds (Non Cash)28.8035.5073.6057.2083.4066.1031.4920.2412.09
Funds from Operations23.90-40.10-118.70-303.40-190.90-118.90-83.82-47.80-28.68
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-182.20-233.70-140.60-44.40-82.60678.30-5.947.1712.57
Cash from Operating Activities-158.30-273.80-259.30-347.80-273.50559.40-89.76-40.63-16.12
Capital Expenditures-1.50-1.90-1.80-2.90-6.80-4.70-6.45-6.24-2.83
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.100.000.000.000.000.00-
Purchase or Sale of Investments220.10409.5036.40206.40249.60-1,308.90170.70-86.85-176.83
Purchase of Investments-359.10-354.20-652.10-956.30-886.40-1,744.60-41.20-256.55-234.89
Sale Or Maturity of Investments579.20763.70688.501,162.701,136.00435.70211.89169.7058.06
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities218.60407.6034.70203.50242.80-1,313.60164.25-93.10-179.67
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-73.00-91.208.30374.704.70278.60504.67139.91166.23
Repurchase of Common Pref Stock-74.10-91.900.000.000.000.000.000.000.00
Sale of Common Pref Stock1.100.708.30374.704.70278.60504.67139.91166.23
Proceedsfrom Stock Options0.000.000.00370.200.00260.00496.41137.09166.16
Issuance or Reduction of Debt, Net-0.30-0.20-0.400.000.000.000.00-0.171.83
Change in Long Term Debt-0.30-0.20-0.400.000.000.000.00-0.171.83
Issuance of Long Term Debt0.000.000.000.000.000.000.000.002.00
Reduction of Long Term Debt-0.30-0.20-0.400.000.000.000.00-0.17-0.17
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities-73.30-91.407.90374.704.70278.60504.67139.74168.06
Net Change in Cash-13.0042.40-216.70230.40-26.00-475.60579.166.02-27.72
Free Cash Flow-159.80-275.70-261.10-350.70-280.30554.70-96.20-46.87-18.95
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Price to Free Cash Flow-----7.40---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments558.40567.90614.90685.40787.60861.20
Short Term Receivables5.3054.306.406.4026.8011.10
Inventories0.000.000.000.000.000.00
Other Current Assets23.9030.009.408.9011.9017.20
Total Current Assets587.60652.20630.70700.70826.30889.50
Net Property, Plant & Equipment11.4012.3013.3013.4014.1015.40
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.00-0.000.00
Other Assets8.5010.603.503.803.904.40
Total Assets607.50675.10647.50717.90844.30909.30
Short Term Debt Incl. Current Port. of LT Debt2.102.102.001.901.902.00
Accounts Payable2.707.3031.2024.2017.8016.40
Income Tax Payable4.404.305.004.803.803.30
Other Current Liabilities60.8068.8077.70111.60121.40136.10
Total Current Liabilities70.0082.50115.90142.50144.90157.80
Long Term Debt5.506.106.607.207.608.10
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities18.2024.30138.20134.30127.40134.10
Total Liabilities93.70112.90260.70284.00279.90300.00
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity513.80562.20386.80433.90564.40609.30
Total Shareholders Equity513.80562.20386.80433.90564.40609.30
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity513.80562.20386.80433.90564.40609.30
Total Liabilities & Stockholders Equity607.50675.10647.50717.90844.30909.30
Book Value Per Share7.848.616.006.837.978.32
Tangible Book Value Per Share7.848.616.006.837.978.32
Full-Time Employees---246--
Price to Book Ratio0.881.391.551.491.020.81
Return on Assets-1.311.17-26.85-8.93-5.82-6.63
Return on Equity-1.761.59-42.28-16.23-10.17-12.00
Return on Invested Capital-10.3829.81-14.64-15.28-6.14-9.91
Quick Ratio8.397.915.444.925.705.64
Current Ratio8.397.915.444.925.705.64

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-53.90169.40-57.60-67.40-35.10-61.20
Depreciation1.101.201.101.201.301.40
Other Funds (Non Cash)4.207.6010.706.307.507.20
Funds from Operations-48.60178.20-45.80-59.90-26.30-52.60
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital38.20-226.50-23.4029.50-32.80-42.80
Cash from Operating Activities-10.40-48.30-69.20-30.40-59.10-95.40
Capital Expenditures0.20-0.20-1.30-0.20-0.10-1.20
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments4.0055.1015.00146.0063.60130.00
Purchase of Investments-113.20-60.40-178.90-6.60-110.00-118.00
Sale Or Maturity of Investments117.20115.50193.90152.60173.60248.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities4.2054.9013.70145.8063.50128.80
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.400.500.00-73.90-17.800.50
Repurchase of Common Pref Stock0.000.000.00-74.10-17.800.00
Sale of Common Pref Stock0.400.500.000.200.000.50
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.00-0.10-0.10-0.100.000.00
Change in Long Term Debt0.00-0.10-0.10-0.100.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.00-0.10-0.10-0.100.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.400.40-0.10-74.00-17.800.50
Net Change in Cash-5.807.00-55.6041.40-13.4033.90
Free Cash Flow-10.20-48.50-70.50-30.60-59.20-96.60

Revenue breakdown

Pharmaceutical Preparations2024: 263.40M 2025: 262.60M
United States2024: 263.40M 2025: 262.60M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.80%5.8M58.7M825.35K
2026-10-159.54%5.6M58.6M793.88K
2026-09-309.20%5.4M58.6M783.83K
2026-09-158.51%5.0M58.6M802.01K
2026-08-318.04%4.7M58.6M785.75K
2026-08-146.93%4.1M58.5M827.06K
2026-07-317.06%4.0M56.6M820.35K
2026-07-157.12%4.0M55.9M829.29K
2026-06-307.64%4.3M55.9M880.91K
2026-06-158.02%4.5M56.0M886.13K
2026-05-298.66%4.7M54.4M877.79K
2026-05-159.31%5.0M54.1M902.86K
2026-04-308.27%4.4M53.4M830.39K
2026-04-158.19%4.4M53.6M853.08K
2026-03-318.41%4.5M53.6M838.46K
2026-03-138.93%4.8M53.6M804.38K
2026-02-278.01%4.3M53.6M873.94K
2026-02-137.55%4.0M53.6M1.27M
2026-01-307.89%4.3M54.0M1.49M
2026-01-159.35%5.1M54.0M1.80M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.004.807.300.000.0000.000.000.988-0.0140.000
call2.002.807.000.000.0000.000.000.980-0.0140.001
call3.003.006.000.0016.2330.000.000.970-0.0140.001
call4.000.804.900.0011.0070.000.000.957-0.0130.001
call5.000.204.102.379.0062.000.000.935-0.0120.001
call6.000.153.101.406.85722.000.000.720-0.0460.004
call7.000.000.900.152.1927530.000.556-0.0550.004
call8.000.000.700.052.5339700.000.432-0.0610.004
call9.000.002.150.051.9411820.000.236-0.0360.003
call10.000.002.150.032.3621,7310.000.206-0.0410.003
call11.000.002.150.202.71610.000.000.188-0.0450.003
call12.000.000.950.003.0230.000.000.175-0.0470.003
call13.000.002.150.003.2950.000.000.165-0.0500.003
call14.000.002.150.003.5380.000.000.157-0.0520.003
call15.000.002.150.003.7590.000.000.151-0.0540.003
call16.000.002.150.003.9600.000.000.146-0.0550.002
put1.000.000.050.006.9910.000.00-0.012-0.0120.000
put2.000.000.950.004.7440.000.00-0.020-0.0140.001
put3.000.001.500.003.3030.000.00-0.030-0.0140.001
put4.000.002.150.002.2640.000.00-0.044-0.0130.001
put5.000.002.150.001.4920.000.00-0.065-0.0110.001
put6.000.000.500.200.99689.000.00-0.163-0.0150.003
put7.000.251.050.702.3491860.00-0.444-0.0540.004
put8.000.003.400.006.3710.000.00-0.685-0.0330.004
put9.000.304.401.596.95817.000.00-0.764-0.0350.003
put10.001.055.200.006.9650.000.00-0.794-0.0400.003
put11.002.056.200.007.3830.000.00-0.812-0.0430.003
put12.004.207.200.007.7480.000.00-0.825-0.0460.003
put13.004.007.300.005.9630.000.00-0.835-0.0480.003
put14.005.009.200.008.3620.000.00-0.843-0.0500.003
put15.006.009.200.006.2680.000.00-0.849-0.0520.003
put16.007.0011.200.008.8640.000.00-0.854-0.0540.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-094Statement of changes in beneficial ownership of securities2026-11-09SEC
2026-11-03S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-09-28S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-09-22144Filing for proposed sale of securities under Rule 144.SEC
2026-09-09144Filing for proposed sale of securities under Rule 144.SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-08-31S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-04144Filing for proposed sale of securities under Rule 144.SEC
2026-08-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-07-09144Filing for proposed sale of securities under Rule 144.SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-258-KCurrent report2026-06-24SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-23144Filing for proposed sale of securities under Rule 144.SEC
2026-06-228-KCurrent report2026-06-22SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-17144Filing for proposed sale of securities under Rule 144.SEC
2026-06-168-KCurrent report2026-06-11SEC
2026-06-028-KCurrent report2026-06-02SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-20144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11001.48K1
2026-100000
2026-090000
2026-080000
2026-070000
2026-060066.04K2
2026-0500452.04K6
2026-040000
2026-03268.07K171.43K1
2026-0200829.38K9
2026-010000
2025-120000
2025-11002.27K1

Institutional holders

Manager% owned
BlackRock, Inc.11.79%
VANGUARD PORTFOLIO MANAGEMENT LLC6.39%
D. E. Shaw & Co., Inc.5.42%
PFIZER INC5.36%
ARMISTICE CAPITAL, LLC4.33%
VANGUARD CAPITAL MANAGEMENT LLC4.21%
TWO SIGMA INVESTMENTS, LP3.99%
STATE STREET CORP3.40%
Qube Research & Technologies Ltd2.47%
JACOBS LEVY EQUITY MANAGEMENT, INC2.19%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.98%
VANGUARD STRATEGIC EQUITY FUND2.65%
iShares Russell 2000 ETF2.40%
VANGUARD EXPLORER FUND1.39%
VANGUARD EXTENDED MARKET INDEX FUND1.13%
Fidelity Small Cap Index Fund1.01%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF1.00%
BlackRock Advantage Small Cap Core Fund0.90%
Federated Hermes MDT Small Cap Core Fund0.87%
iShares Russell 2000 Value ETF0.79%

OakChart. ARVN. Cached 15 minutes.